OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now funded across Canada through both public and private healthcare plans.…
I-Mab Presents Positive Phase 1b Data for Givastomig in Combination with Nivolumab and Chemotherapy in 1L Gastric Cancer at ESMO GI 2025 I-Mab (NASDAQ: IMAB), a U.S.-based global biotechnology company focused on the development of precision immuno-oncology therapies, has unveiled…
Suriname Becomes First Amazon Nation to Earn WHO Malaria-Free Certification In a historic public health milestone, the Republic of Suriname has been officially certified as malaria-free by the World Health Organization (WHO), becoming the first country in the Amazon region…
BioMarin Finalizes Acquisition of Inozyme Pharma, Strengthening Rare Disease Portfolio with INZ-701 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has officially completed the acquisition of Inozyme Pharma, Inc. (Nasdaq: INZY), a move that underscores its continued commitment to addressing rare and life-threatening…
WHO Issues Global Safety Alert Over Vision Loss Risk Linked to Semaglutide-Based Medications The World Health Organization (WHO) has issued a global safety communication directed at healthcare professionals and regulatory authorities, warning of a potential but serious adverse effect associated…
WHO Scientific Advisory Group Releases In-Depth Report on the Origins of COVID-19 Amid Ongoing Calls for Transparency and Global Cooperation The World Health Organization (WHO) has taken another step forward in the complex and politically sensitive investigation into the origins…
WHO Launches Landmark Global Initiative to Advance Health Equity for Over 1.3 Billion People with Disabilities In a pivotal step toward realizing global health equity, the World Health Organization (WHO) officially launched the WHO Disability Health Equity Initiative on June…
UCB Announces Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder, Marking a Major Step Forward in Rare Epilepsy Treatment UCB, a global biopharmaceutical company committed to developing innovative therapies for neurological and immunological conditions, has announced positive top-line…
European Commission Grants Approval for Eylea™ 8 mg with Extended 6-Month Dosing Interval in Patients with nAMD and DME The European Commission (EC) has officially approved a label extension for Eylea™ 8 mg (aflibercept 8 mg, 114.3 mg/mL solution for…
Biogen Unveils New Data Underscoring the Long-Term Benefits and Advancements of Nusinersen in Spinal Muscular Atrophy Treatment Biogen, a global leader in neuroscience, has announced compelling new data that reinforces the clinical value and therapeutic potential of nusinersen, a pioneering…
Viatris Reports Positive Top-Line Results from Pivotal Phase 3 VEGA-3 Trial of MR-141 for Presbyopia, Underscoring Its Potential as a Non-Invasive Vision Correction Therapy Viatris, a global healthcare company committed to increasing access to high-quality medicines and health solutions worldwide,…
BeOne Medicines Showcases Bold Vision and Expansive Oncology Pipeline at 2025 R&D Day BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, delivered a comprehensive update to investors today during its highly anticipated Research and Development (R&D) Day. The event spotlighted…